(PRWEB) December 11, 2009
Therapure Biopharma Inc. today announced the signing of an exclusive supply agreement with Akorn Inc. (NASDAQ: AKRX). This agreement will support Akorn’s new product development initiatives.
Under the terms of the partnership, Therapure Biopharma will provide product formulation, process development, and sterile fill/finish services to support the development of new hospital products by Akorn. Therapure Biopharma will provide these services in its Health Canada licensed facility in Mississauga, Ontario.
“We are proud that Akorn has chosen Therapure Biopharma as a strategic partner for the development of these new products,” said Thomas Wellner President and CEO of Therapure Biopharma Inc. “Therapure Biopharma has experience in meeting the needs of customers for specialized fill/finish services and we were able to respond quickly to Akorn’s particular requirements.”
“Akorn carries a broad catalogue of sterile specialty pharmaceutical products”, said Sean Brynjelsen, Akorn’s Vice President of New Business Development. “Therapure Biopharma was able to quickly respond to our need for specialty formulation and fill/finish services. The signing of this exclusive supply agreement reinforces Akorn’s commitment to expanding our portfolio through partnering.”
About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.
For more information, please visit: http://www.therapurebio.com
About Akorn, Inc.
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.
For more information, please visit http://www.akorn.com.
# # #